A detailed history of Boothbay Fund Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 44,000 shares of APLS stock, worth $1.46 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
44,000
Holding current value
$1.46 Million
% of portfolio
0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $674,040 - $881,887
12,169 Added 96.15%
24,825 $1.46 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $178,494 - $311,524
4,806 Added 61.22%
12,656 $757,000
Q3 2023

Nov 14, 2023

SELL
$23.65 - $89.22 $457,485 - $1.73 Million
-19,344 Reduced 71.13%
7,850 $298,000
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $470,508 - $572,550
6,136 Added 29.14%
27,194 $2.48 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $981,092 - $1.41 Million
21,058 New
21,058 $1.39 Million
Q2 2022

Aug 15, 2022

SELL
$35.07 - $59.21 $1.04 Million - $1.75 Million
-29,606 Reduced 85.39%
5,065 $229,000
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $1.09 Million - $2.42 Million
34,671 New
34,671 $1.14 Million
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $234,310 - $363,653
-9,448 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $169,213 - $418,829
9,448 New
9,448 $253,000
Q1 2019

May 15, 2019

SELL
$12.81 - $19.82 $333,060 - $515,320
-26,000 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$11.47 - $18.71 $298,220 - $486,460
26,000 New
26,000 $343,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.